Compare · PACB vs RVTY
PACB vs RVTY
Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PACB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $9.69B, about 19.5x PACB ($496.8M).
- Over the past year, PACB is up 40.4% and RVTY is down 7.8% - PACB leads by 48.1 points.
- RVTY has been more active in the news (7 items in the past 4 weeks vs 6 for PACB).
- PACB has more recent analyst coverage (24 ratings vs 18 for RVTY).
- Company
- Pacific Biosciences of California Inc.
- Revvity Inc.
- Price
- $1.60+0.63%
- $86.69+0.03%
- Market cap
- $496.8M
- $9.69B
- 1M return
- +19.40%
- -1.41%
- 1Y return
- +40.35%
- -7.79%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- News (4w)
- 6
- 7
- Recent ratings
- 24
- 18
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Latest PACB
- SEC Form DEFA14A filed by Pacific Biosciences of California Inc.
- SEC Form DEF 14A filed by Pacific Biosciences of California Inc.
- PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
- PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
- PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples
- SEC Form 4 filed by Gibson Christopher
- SEC Form 4 filed by Gibson James R Ii
- Amendment: SEC Form SCHEDULE 13G/A filed by Pacific Biosciences of California Inc.
- Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
Latest RVTY
- SEC Form 8-K filed by Revvity Inc.
- Revvity Board Declares Quarterly Dividend
- SEC Form 4 filed by Gonzales Anita
- Revvity to Present at Upcoming Investor Conferences
- Revvity downgraded by Barclays with a new price target
- Revvity to Hold Earnings Call on Tuesday, May 5, 2026
- Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
- SEC Form 4 filed by Gonzales Anita
- SEC Form DEFA14A filed by Revvity Inc.
- SEC Form DEF 14A filed by Revvity Inc.